The Objective of our study was to evaluate the clinical and biochemical effects of (SGLT2) inhibitors as a fourth oral anti-diabetic drug in patients with Type-2 diabetes mellitus (T2DM). Here, SLC5A2 is linked to type 2 diabetes mellitus.